HLTRF Stock - HLS Therapeutics Inc.
Unlock GoAI Insights for HLTRF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $56.62M | $63.07M | $61.47M | $60.01M | $56.11M |
| Gross Profit | $47.62M | $55.45M | $56.49M | $56.04M | $52.48M |
| Gross Margin | 84.1% | 87.9% | 91.9% | 93.4% | 93.5% |
| Operating Income | $-7,686,000 | $-10,349,000 | $-13,440,000 | $-6,284,000 | $-12,087,000 |
| Net Income | $-19,655,000 | $-27,531,000 | $-23,598,000 | $-13,117,000 | $-15,331,000 |
| Net Margin | -34.7% | -43.6% | -38.4% | -21.9% | -27.3% |
| EPS | $-0.62 | $-0.85 | $-0.73 | $-0.41 | $-0.48 |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
Visit WebsiteEarnings History & Surprises
HLTRFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.06 | $-0.12 | -100.3% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.07 | $-0.09 | -15.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.12 | $-0.14 | -16.5% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.09 | $-0.10 | -7.6% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.12 | $-0.15 | -22.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.15 | $-0.18 | -17.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.16 | $-0.19 | -19.9% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.10 | $-0.17 | -82.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.11 | $-0.21 | -100.5% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.12 | $-0.29 | -141.1% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.12 | $-0.18 | -51.7% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.07 | $-0.20 | -185.7% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.07 | $-0.28 | -300.0% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.10 | $-0.13 | -30.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.15 | $-0.07 | +53.3% | ✓ BEAT |
Frequently Asked Questions about HLTRF
What is HLTRF's current stock price?
What is the analyst price target for HLTRF?
What sector is HLS Therapeutics Inc. in?
What is HLTRF's market cap?
Does HLTRF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HLTRF for comparison